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Abstract
Background: Perioperative hemorrhage may depend on coagulation competence and this study evaluated the
influence of coagulation competence on blood loss during cystectomy due to bladder cancer.
Methods: Forty patients undergoing radical cystectomy were included in a randomized controlled trial to receive
either lactated Ringer’s solution or Dextran 70 (Macrodex ®) that affects coagulation competence.
Results: By thrombelastography evaluated coagulation competence, Dextran 70 reduced “maximal amplitude” (MA)
by 25 % versus a 1 % reduction with the administration of lactated Ringer’s solution (P <0.001). Blinded evaluation
of the blood loss was similar in the two groups of patients - 2339 ml with the use of Dextran 70 and 1822 ml in
the lactated Ringer’s group (P = 0.27). Yet, the blood loss was related to the reduction in MA (r = −0.427, P = 0.008)
and by multiple regression analysis independently associated with MA (P = 0.01). Thus, 11 patients in the dextran
group (58 %) developed a clinical significant blood loss (>1500 ml) compared to only four patients (22 %) in the
lactated Ringer’s group (P = 0.04).
Conclusions: With the use of Dextran 70 vs. lactated Ringer’s solution during cystectomy, a relation between
hemorrhage and coagulation competence is demonstrated. Significant bleeding develops based on an about 25 %
reduction in thrombelastography determined maximal amplitude. A multivariable model including maximal
amplitude discriminates patients with severe perioperative bleeding during cystectomy.
Trial registration: The study was accepted on January 7th, 2013 at www.clinicaltrialsregister.eu EudraCT 2012-005040-20.
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Background
For patients exposed to a massive blood loss, maintained
coagulation competence is important [1–3]. It is less
clear whether coagulation competence influences bleed-
ing during elective surgery. During surgery the circula-
tion is supported by crystalloids, but about 30 % of the
administered volume is “lost” to the interstitial space
even when the circulating blood volume is reduced due
to hemorrhage [4]. It therefore remains an option to
administer a colloid to patients during major surgery
because a colloid stays within the circulation and may
even recruit fluid to the vasculature. Yet, it is a concern
that synthetic colloids impair coagulation competence
by reducing clot propagation and strength by affecting
polymerization of fibrinogen [5–7].
We evaluated the importance of coagulation compe-
tence for the perioperative blood loss during cystectomy.
The first part of this evaluation used Hydroxyethyl
Starch (HES 130/0.4) vs. lactated Ringer’s solution (LR)
and demonstrated a doubling of the perioperative blood
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loss [8]. Here we used Dextran 70 vs. LR to manipulate
coagulation competence during cystectomy to evaluate
whether the perioperative blood loss is related to reduc-
tion in coagulation competence as determined by throm-
belastography (TEG). Also the design of the study
allowed for comparison of the use of Dextran 70 and LR
on patient outcome and the cost associated with admin-
istration of volume.
Methods
This randomized controlled trial was based on plasma
collected from participants in a colloid vs. crystalloid
trial [8]. The study was approved by Rigshospitalet,
University of Copenhagen, after approval had been
obtained from the ethics committee in the Capital
Region of Denmark (H-1-2012-135), and registered at
www.clinicaltrialsregister.eu with Trial Registration
Number EudraCT 2012-005040-20. The trial was moni-
tored by the Agency for Good Clinical Practice at the
University of Copenhagen and the Declaration of Helsinki
criteria were followed [9].
Conduct of the trial and safety of the participants were
overseen by the authors who gathered the data that
remained confidential throughout the process. The
authors were involved in all stages of manuscript
generation and vouched for completeness and accuracy.
No third party influenced the study design, data analysis,
or reporting.
Screening and randomization took place between
February 12th 2013 and July 8th 2014. At least 24 h
before surgery written informed consent was obtained
from the patients. We excluded patients from this
investigator-initiated, prospective, blinded trial if con-
sent was withdrawn. Forty out of 99 patients scheduled
for elective cystectomy were randomized to receive the
recommended maximum volume (25 mL/kg) of either
6 % Dextran 70 (Macrodex®, Meda AB, Solna, Sweden)
or LR by computer-generated allocation sequence
(Fig. 1). We included patients older than 18 years.
Scheduled for elective open cystectomy with no history
of heart or hepatic insufficiency, disability of coagula-
tion, intra-cerebral hemorrhage, or hemodialysis. If a
patient used medication that was considered to affect
coagulation competence, that medication was paused
5 days prior to surgery according to national guidelines.
Interventions
The patients were allowed to eat solid foods up to 6 h
and to drink clear fluids until 2 h before surgery. An IV
line was established and flushed with the randomized
Fig. 1 Randomization of Study Patients. Consort study flow diagram
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fluid placed in an opaque bag to blind the surgical nurse
who recorded the volume of lost blood. After induction
of anesthesia a catheter was placed in the radial artery of
the non-dominant arm and connected to a Nexfin monitor
(Bmeye B.V, Amsterdam, The Netherlands). From the
blood pressure curve, Nexfin estimates a beat-to-beat
stroke volume (SV) and thereby cardiac output (CO)
by use of a non-linear three-component model of
arterial impedance as evaluated by modified Model-
flow technology [10].
For induction of anesthesia remifentanil infusion
(0.5 μg kg−1 min−1) was initiated and when the patient
reported sedation propofol (2.0 mg kg−1) was adminis-
tered. Propofol (5–10 mg kg−1 h1) and remifentanil
(1.75–2.25 mg h−1) were used to maintain anesthesia. In
the horizontally placed patient normovolemia was estab-
lished, i.e. it was secured that after eventual repeated
administration of 200 mL of the randomized fluid, SV
increased by less than 10 % according to “goal directed
fluid therapy” (GDT) criteria [11].
Heart rate (HR), mean arterial pressure (MAP), SV,
and CO were determined after induction of anesthesia
and insertion of the arterial catheter (T1), after resection
of the urinary bladder (T2), at the end of surgery (T3),
and 2 h thereafter in the recovery room (T4). If systolic
pressure was below 80 mmHg, 5–10 mg of ephedrine
was administered. Arterial blood was analysed by TEG:
clot initiation (R-time), rate of development (Angle), for-
mation (maximal amplitude, MA), and lysis after 30 min
(Ly30) depicting hemostatic competence (TEG 5000,
Haemoscope Corporation, Niles, IL) [12]. We also ana-
lysed blood for hemoglobin, creatinine, international
normalised ratio (INR), platelets, dimer, and fibrinogen.
Furthermore, blood was drawn from the central venous
catheter for lactate and blood gas variables (ABL 825,
Radiometer, Copenhagen, Denmark).
To avoid excessive administration of Dextran 70, both
groups of patients received either LR or 5 % Human
Albumin (HA) if considered in need by the anesthetist
after infusion of the allocated fluid (non-study fluid).
Fluid balance was determined at T2, T3, and T4. Two
surgeons who together had completed more than 1100
cystectomies carried out the procedures.
The primary outcome variables were coagulation com-
petence and the perioperative blood loss. We also com-
pared the use of dextran or LR on patient outcome
defined as a straight postoperative track: length of hospital
stay ≤7 days without complications requiring treatment
and on the cost associated with fluid administration to
support the circulation.
Cost-effectiveness analysis
The cost-effectiveness ratio is defined as the cost (C) per
successfully treated patient (E), i.e., cost to keep a patient
free of complications. The cost-effectiveness analysis used
the difference in cost divided by the difference in benefit
(C/E) [13] based on the 2015 price (Data-Ware-House ®,
Rigshospitalet) for Dextran 70 (4.51 $ per 500 ml), LR
(1.19 $ per 1000 ml), packed red blood cells (46.84 $ per
250 ml), and HA (15.60 $ per 250 ml).
Statistical methods
Patients were analysed in the group to which they were
assigned (Table 1). The sample size calculation was
based on data from a study comparing the effect on
hemorrhage during cystectomy with the use of HES
130/0.4 vs. LR [8]. The blood loss was 2181 vs.1370 ml
with a SD of 1190 vs. 603 ml [8]. The study was powered
to detect a difference in blood loss of 800 ml between
administration of Dextran 70 and LR with a two-sided
alpha level of 0.05 and a power of 80 % for t-test with
correction for multiple comparisons. Consequently, a
sample size of 20 patients per group was included.
The statistical analyses were performed before break-
ing the randomization code and data were analysed from
the modified intention-to-treat population, defined as all
randomly assigned patients except those who could be
excluded without the risk of bias (Fig. 1). We used two-
sided or unadjusted chi-square tests with odds ratio
(OR) and t-test and Fisher’s exact test for continuous
and dichotomous variables, respectively (SPSS version
20.0). Test for differences were performed using Pearson’s
test, χ2 test for categorical data, and analysis of variance
or Mann-Whitney U-test and Wilcoxon signed ranks test
for continuous data when appropriate. Means and stand-
ard deviation (SD) or confidence interval (CI) are given,
For possible determinants of perioperative bleeding,
multiple logistic regression analysis defined variables
from TEG and plasma hemostatic analyses that were
independently associated with severe intraoperative
bleeding (>1.5 l).
Also receiver operating characteristic (ROC) curves
were used to predict perioperative bleeding. Areas under
the ROC curve with the 95 % confidence Intervals (CI)
were calculated. Optimal cut-points were obtained by
minimizing the distance between the ROC curve and the
upper left corner of the curve. Results are presented with
95 % CI and a two-sided P value <0.05 was considered to
indicate statistical significance.
Results
Patients were randomized into two groups (Fig. 1).
There was no significant intergroup difference in base-
line data including preoperative disease among patients
(Table 1). After induction of anesthesia, five patients
(26 %) in the colloid group were intravascular hypovol-
emic according to GDT criteria as compared to seven
patients (39 %) in the crystalloid group, P = 0.495. In the
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colloid group patients received 24 (18 to 25) ml kg−1
Dextran 70 since three patients were considered to be
hemodynamic stable before the intended volume
(25 ml kg−1) was infused.
The perioperative blood loss was 2339 (1630 to 3048)
ml in the colloid group and not significantly different in
the LR group: 1822 (1160 to 2484) ml, P = 0.2 (Table 2).
Yet, more patients in the dextran than in the LR group
were exposed to clinical severe hemorrhage: 58 % vs.
22 % lost more than 1500 ml blood, OR = 4.8 (1.1 to
20.2), P = 0.04. In the LR group, one significant bleeding
episode (5.5 l) was because of injury to the common iliac
vein and in this case hemorrhage cannot be ascribed to
coagulation competence. If that patient is eliminated
Table 2 Perioperative fluid administration, blood loss, and fluid balance
Dextran (n = 19) Lactated Ringer’s (n = 18) P value
Intravenous fluids
Lactated Ringer’s 987 ± 614 691–1283 2883 ± 690 2540–3226
Dextran 70 1886 ± 355 1765–2006 –
Packed red blood cells 597 ± 613 302–893 313 ± 545 42–684 0.14
HA 118 ± 210 17–220 519 ± 379 331–708 0.001
FFP 201 ± 362 0–251 102 ± 301 0–251 0.37
Platelets 92 ± 21 0–202 0 ± 0 0–0 0.10
Total fluids balance
Total fluid infusion 4157 ± 1779 3300–5014 4121 ± 1352 3450–4794 0.95
Total fluid lost 2638 ± 1491 1918–3356 2196 ± 1380 1509–2881 0.29
Fluid balance 1520 ± 668 1198–1842 1925 ± 696 1580–2272 0.03
Blood loss
Total blood loss 2339 ± 1470 1630–3048 1822 ± 1240 1160–2484 0.27
Fluid balance was calculated from the administered solutions, transfusion of blood products, urine output, and blood loss (suction and drainage) during
anesthesia and in the recovery room. Blood products included packed red blood cells, fresh-frozen plasma (FFP), and platelets. Values are expressed as means with
sd and 95 % confidence interval. P-values by univariate analysis
Table 1 Patient characteristics of the study groups
Dextran (n = 19) Lactated Ringer’s (n = 18) P value
Preoperative variables
Age – yrs. 68.1 (61.9–74.3) 67.8 (64.1–71.6) 0.94
Male – sex 15 (79 %) 12 (67 %) 0.48
Body weight (kg) 77.3 (56–99) 77.2 (52–110) 0.97
BMI – kg/m2 25.3 (24.1–26.8) 24.8 (23.7–28.3) 0.66
ASA – class 2.0 (1–3) 2.0 (1–3) 0.48
Cardiopulmonary disease 11 (58 %) 11 (61 %) 1.00
Intraoperative variables
Anesthesia (min) 210 (198–275) 210 (211–260) 0.93
Blood loss >1500 ml 11 (58 %) 4 (22 %) 0.04
PRBCs 12 (63 %) 5 (28 %) 0.04
Ephedrine (mg) 16.7 (8.8–24.5) 29.2 (20.2–38.2) 0.03
Postoperative variables
Straight track a 4 (21 %) 11 (61 %) 0.02
Days until bowel movement 3.0 (1–7) 2.5 (2–30) 0.60
Complications 7 (37 %) 3 (17 %) 0.26
Re-operations 5 (26 %) 2 (11 %) 0.40
Hospital stay (days) 9.0 (5–24) 7.0 (6–92) 0.69
Values are either numbers (n), percentages (%), means or medians with 95 % confidence interval, or range. P-value by univariate analysis. BMI, body mass index;
ASA class, American Society of Anesthesiologists, PRBC, packed red cells, a length of stay, ≤ 7 days without complications requiring treatment
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from the analysis, the loss of blood was 2339 (1630 to
3048) ml vs. 1610 (1090 to 2130) ml in the dextran and
LR group, respectively, P = 0.048. Table 2 also presents
IV administration of study as well as non-study fluids.
Transfusion was initiated at a hemoglobin of 4.9 mmol l
−1 and the transfusion of packed red blood cells was 597
(302 to 893) vs. 313 (42 to 584) ml (P = 0.14) in the
Dextran 70 and LR group, respectively. Thus, 12 patients
(63 %) in the colloid group were provided with blood vs.
five patient (28 %) in the crystalloid group, OR = 4.5 (1.1
to 17.9), P = 0.04. The fluid balance was positive by 1520
(1198 to 1842) ml in the dextran group and by 1925
(1580 to 2272) ml in the LR group (P = 0.03) also with
more patients in the RL group having a positive fluid
balance exceeding 1500 ml, 78 % vs. 21 %, OR = 13.1 (2.7
to 62.8) P = 0.001. The dextran group received 17 mg
ephedrine and the LR somewhat more (29 mg, P = 0.03)
resulting in no differences in MAP, SV or CO between the
two groups of patients.
Table 3 presents results from TEG analyses. The lowest
values of RT, Angle and MA in the analyses was observed
in the dextran group at the end of anesthesia (P <0.001).
Platelets values decreased in both groups during
anesthesia (from 205 ± 69 to 141 ± 45 109/l in the dextran
group, P <0.001, and from 243 ± 65 to 198 ± 72 109/l in
the LR group) P <0.001, whereas dimer increased simi-
larly in both groups (from 0.59 ± 0.50 to 1.08 ±
0.57 mg/l (dextran group) and from 0.38 ± 0.12 to 1.18 ±
0.65 μmol/ l (LR group); P <0.001). Hemoglobin decreased
more (5.2 ± 0.6 vs. 6.1 ± 0.9 mmol/l) in the dextran group
compared to the LR group, P <0.001.
The blood loss was related to the decrease in MA
(r = −0.407 (95%CI −0.632 to −0.101) P = 0.008 (Fig. 2),
but not to R-time, Angle, or Ly30. Univariate analyses
defined four TEG variables (Table 3) important for a
blood loss >1.5 l and included in a multiple logistic
regression analysis. Concerning the influence of the
coagulation variables as predictors for what was con-
sidered a significant blood loss (>1.5 l), only MA was
important (Table 4). Thus, MA was used to build a
ROC curve for patients receiving Dextran 70 or RL
with a blood loss >1.5 l. The areal under the curve
(AUC) was 0.69 (0.51–0.87) and the optimal cut-point
for MA was 81 % of the value at T1 (about 52 mm), pro-
viding 80 % sensitivity and 53 % specificity (P = 0.04)
equating a likelihood ratio (sensitivity/1-specificity) = 1.90
(Fig. 3).
Creatinine increased (>120 mol l−1) at the end of sur-
gery for five patients (26 %) in the dextran group com-
pared with normal values in the LR group (P = 0.046),
Table 3 Comparison of the coagulation variables between the study groups
Variable Dextran (n = 19) Lactated Ringer’s (n = 18) P value
Reaction time (min)
T1 5.93 5.34–6.54 5.25 4.69–5.82 0.100
T2 5.85 5.34–6.36 4.70 4.19–5.22 0.002
T3 5.90 5.20–6.59 4.26** 3.83–4.70 0.001
T4 5.91 5.36–6.45 4.31* 3.74–4.89 0.001
Angle (°)
T1 70.72 68.76–72.68 71.12 68.03–74.21 0.817
T2 60.87*** 56.85–64.90 72.84 70.56–75.12 0,000
T3 54.92*** 50.53–59.30 72.57 69.95–75.18 0,000
T4 58.92*** 55.01–62.82 72.39 70.32–74.46 0,000
Maximal amplitude (mm)
T1 65.17 61.93–68.42 63.98 60.25–67.72 0.614
T2 54.30*** 49.53–59.08 64.39 61.39–67.40 0.001
T3 48.92*** 44.65–53.19 62.08 58.9–65.27 0.000
T4 49.08*** 44.83–53.34 63.11 52.33–59.09 0.000
Lysis after 30 min (%)
T1 1.52 0.64–2.42 2.15 0.82–3.50 0.403
T2 1.17 0.31–2.04 1.69 0.57–2.80 0.444
T3 0.71 0.27–1.15 1.57 0.71–2.42 0.066
T4 1.05 0.21–1.89 2.30 0.63–3.97 0.146
TEG analysis after induction of anesthesia (T1); after resection of the urinary bladder (T2); at the end of surgery (T3), and 2 h thereafter in the recovery room (T4).
Values are mean with 95 % confidence interval. P-value by univariate analysis
*P <0.05, **P <0.01 and ***P <0.001 difference from induction of anesthesia (T1) within the group
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but no participant was in need of hemodialysis. Also in
the LR group 61 % of the patients had a postoperative
straight track compared to only 21 % in the dextran group,
OR = 5.9, 95%CI (1.38 to 25.23), P = 0.02 (Table 1). The
number of patients with at least one treated postoperative
complication was 7 (37 %) vs. 3 (17 %) (OR = 2.9, 95 % CI
(0.6 to 13.8) P = 0.26). Five (26 %) vs. 2 (11 %) patients
were re-operated in the dextran and LR group, respect-
ively (OR = 2.9, 95 % CI (0.5 to 17.1) P = 0.40). No patient
needed re-operation due to intestinal dysfunction. Thus,
the length of hospital stay was similar among the two
groups, P = 0.69.
The cost of fluid infusions per patient was119 vs. 95 $
(Dextran 70 vs. LR), while the cost-effectiveness ratio (the
cost of successfully treating one patient with Dextran 70
or LR) was 188 (119 × 19 /12) and 114 (95 × 18/15) $ to
avoid complications requiring treatment in the dextran
and LR group of patients, respectively.
Discussion
This randomised study used either Dextran 70 or
lactated Ringer’s solution to support the circulation
according to individualized goal-directed principles
during cystectomy to evaluate the importance of coagu-
lation competence for the perioperative loss of blood
[14, 15]. Coagulation competence was evaluated by
TEG and the perioperative blood loss was related to re-
duction in MA by 25 %.
Perioperative hemorrhage tended to increase when
Dextran 70 rather than LR was administered and more
patients in the dextran group were exposed to a severe
blood loss as identified by a larger than a 1500 ml, blood
loss (a class IV blood loss) and oxygen transport to the
tissue might become affected [16]. Furthermore, three
times as many patients receiving LR than dextran had a
straight postoperative track supporting that Dextran 70
should not be the first choice colloid for support of the
circulation during major surgery.
Dextran is used to support the circulation during
major bleeding but obviously with moderate administra-
tion for minor surgery administration of Dextran affects
coagulation competence only modestly [17]. In accord-
ance with the CRISTAL trial addressing hypotensive
patients under intensive care [18], the present investiga-
tion did not show significant difference in transfusion
requirements between the two groups of patients.
Fig. 2 Maximal amplitude (MA) in relation to blood loss. Change in coagulation competence at the end of anesthesia expressed as MA by
thrombelastography and blood loss in patients undergoing open radical cystectomy receiving either Dextran ● or lactated Ringer’s solution (RL)
▲(n = 37), r = −0.407 (95%CI −0.632 to −0.101), P = 0.008
Table 4 Coagulation variables in predicting the development of severe blood loos during anesthesia
Variable Regression coefficient (β) Standard errors (SE) P-value Odds ratio (eβ) 95 % CI
RT 0.61 0.86 0.48 1.84 0.34–9.95
Angle −1.15 1.18 0.33 0.32 0.03–3.22
MA 2.48 1.25 0.04 11.88 1.03–136.9
Ly30 −0.37 0.84 0.66 0.69 0.13–3.62
Constant −0.96 1.12
RT reaction time, Angle angle in degrees, MA maximal amplitude, Ly30 amplitude reduction after 30 min
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Nevertheless, the transfusion requirement tended to be
larger with administration of Dextran 70.
LR reverses hypovolemia by plasma volume expansion
[19]. Animal experiments and computer simulation based
on fluid volume kinetics suggest that initial fluid volume
resuscitation in a hypotensive patient may include admin-
istration of 600–750 ml of crystalloid fluid or 100 ml
Dextran 70 [20]. Conversely, a positive postoperative fluid
balance may provoke gut edema and contribute to intes-
tinal dysfunction, postoperative complications, and ex-
tended hospital stay [21–23]. Thus it is a worry that the
patients provided LR received almost 50 % more fluid,
besides more inotrope medication compared those pro-
vided with dextran, but there appeared to be no difference
in complication among the two group of patents.
If one treatment is more effective and less costly than
another, that treatment is considered dominant and the
use of LR seems to be the dominant strategy. Equally
Kruer & Ensor argue that crystalloids are associated with
greater effectiveness and lower cost compared with col-
loids in regard to morbidity [24].
We evaluated the predictive value of TEG variables for
perioperative bleeding. Changes in MA in patients with
blood loss >1.5 I provides the areal under the curve on
0.69 besides 80 % sensitivity and 53 % specificity. The
optimal cut-point for MA was 81 % (52 mm) (Fig. 3)
and MA was the best predictor (Table 4) to discriminate
between blood loss >1.5 l or ≤1.5 l. In a prospective trial,
255 consecutive patients were studied to compare the
ability of TEG (ROTEG™) to predict postoperative blood
loss, and the angle was the best predictor of a blood
loss >500 ml [25]. Yet, in a recent study comparing hydro-
xyethyl starch and lactated Ringer’s during cystectomy there
was correlation between the perioperative blood loss and
MA, with an optimal cut-point for MA on 86 % (54 mm),
resulting in 88 % sensitivity and 69 % specificity [8].
There are limitations to this investigation: the design
has a short observation period and a larger cohort is
needed to evaluate an effect on survival or other major
outcomes. Three patients were excluded from the trial
after randomization (Fig. 1). Furthermore, in one patient
hemorrhage seemed to be related to injury to the common
iliac vein and one patient was hospitalized for an excep-
tionally long time, both events not necessarily related to
the type of fluid administered. Furthermore, the different
volume of albumin administration in the groups may
interfere with outcomes such as hospital stay and postop-
erative complications.
Conclusion
With the use of Dextran 70 vs. lactated Ringer’s solution
during cystectomy it is demonstrated that there is a rela-
tion between hemorrhage and coagulation competence.
During critical bleeding there is an about 25 % reduction
in thrombelastography determined “Maximal Amplitude”,
which discriminates those with severe perioperative bleed-
ing. Also the design of the study allowed for demonstra-
tion of greater effectiveness and lower cost with the use of
LR compared to Dextran 70 although the length of hos-
pital stay was equal.
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